Post-Coronary Artery Bypass Grafting Outcomes of Patients with/without Type-2 Diabetes Mellitus and Chronic Kidney Disease Treated with SGLT2 Inhibitor Dapagliflozin: A Single-Center Experience Analysis.
Razan Al NamatLetiția Doina DuceacLiliana ChelaruMarius Gabriel DabijaCristian GuțuConstantin MarcuMaria Valentina PopaFlorina PopaElena Roxana Bogdan GorofteiElena TarcaPublished in: Diagnostics (Basel, Switzerland) (2023)
Regarding the patients' cardiac statuses, the results from our single-center analysis revealed a significant decrease in ischemic risk (H-FABP and hs-cTnI levels) with improvements in mean ejection fraction, glycemic status, and renal function in patients post-CABG with/without T2DM, with/without CKD, and with SGLT2 inhibitor dapagliflozin treatment while undergoing cardiac rehabilitation.
Keyphrases
- ejection fraction
- chronic kidney disease
- coronary artery bypass grafting
- end stage renal disease
- aortic stenosis
- coronary artery disease
- percutaneous coronary intervention
- type diabetes
- peritoneal dialysis
- left ventricular
- heart failure
- binding protein
- prognostic factors
- oxidative stress
- blood brain barrier
- insulin resistance
- weight loss
- combination therapy
- breast cancer risk